High sensitivity C‐reactive protein may predict angiographic severity of coronary artery disease

  • Tajfard M & al.
  • J Cell Physiol
  • 12 Dec 2018

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Elevated serum high sensitivity C‐reactive protein (hs‐CRP) levels are significantly associated with severity of coronary artery disease (CAD) on coronary angiography, suggesting its value as a biomarker for predicting CAD.

Why this matters

  • Findings suggest serum hs‐CRP may be a simple, reproducible and reliable biomarker to predict severity of CAD risk and help physicians in prognosis and diagnosis of cardiovascular disease.

Study design

  • This case-control study included 2346 participants (with CAD and subjected to angiography, 1187; control group, 1159) from September 2011 to May 2013.
  • Glycaemic profile, lipid profile, hs‐CRP levels and severity of CAD were compared between the two groups.
  • Funding: Mashhad University of Medical Sciences and University Putra Malaysia.

Key results

  • Serum hs‐CRP levels were higher in those with severe coronary disease, who had stenosis ≥50% in at least one coronary artery (P<.001 for all and showed significant association with severity of coronary artery disease vs control group.>
  • After adjustment for conventional risk factors, smoking habits, fasting blood glucose, total cholesterol, high‐density lipoprotein, hs‐CRP, blood pressure, anxiety, dietary intake of vitamin E and cholesterol were associated with severity of CAD (P<.05>
  • The area under the receiver operating characteristic curve for serum hs‐CRP was 0.869 (P<.001 and optimal values for the cut point hs to predict severity of cad were mg specificity>

Limitations

  • Overestimation or underestimation of mean scores.
  • Findings were not generalised to all patients with cardiovascular disease.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit